Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

COMPLETED

NCT07740187

A Clinical Trial to Evaluate the Effects of a Supplement on Markers of Female Fertility

Sponsor: WeNatal

View on ClinicalTrials.gov

Summary

This study evaluates the effects of a daily dietary supplement (WeNatal For Her) on markers of female fertility, reproductive health, and sexual health over three menstrual cycles. Forty female participants who are currently trying to conceive will take three capsules of the supplement each morning with their first meal. The study is a single-arm, unblinded hybrid trial. Participants will complete questionnaires at Baseline and on Days 2-5 of Cycles 1, 2, and 3, and will attend a local Labcorp location for blood draws at Baseline and at Cycle 3. Primary outcomes include blood-based biomarkers of female fertility (e.g., AMH, FSH, Estradiol), while secondary outcomes capture self-reported perceptions of reproductive health, energy levels, mood, and overall well-being.

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-04-15

Completion Date

2026-02-12

Last Updated

2026-07-31

Healthy Volunteers

Yes

Conditions

Female Infertility Reproductive Health Fertility Hormonal Imbalance Ovarian Reserve

Interventions

DIETARY_SUPPLEMENT

WeNatal For Her Supplement

All 40 participants take three capsules of the WeNatal For Her supplement daily in the morning with their first meal for three menstrual cycles.

Inclusion Criteria: * Be female. * Be aged 18-45. * In the past three menstrual cycles, has experienced issues with all of the following: Low energy levels and fatigue * Bloating * Breast tenderness * Irritability or mood swings. * Currently trying to conceive. * Anyone who is generally healthy - does not live with any uncontrolled chronic disease. * Not planning on introducing any products or any new forms of prescription medication or supplements that target female fertility for the study duration. * Has a regular menstrual cycle between 21 and 35 days in length and is able to predict the dates of their upcoming periods. * Resides in the United States. * Not currently partaking in another research study and will not be partaking in any other research study for the next three menstrual cycles and at any point during this study's duration. * Willing to avoid all other prenatal vitamins for the duration of this study. Exclusion Criteria: * Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * Anyone with any allergies or sensitivities to any of the study product ingredients. * Any women who are currently pregnant or breastfeeding. * Anyone taking anticoagulant or "blood thinning" medication. * Anyone taking bisphosphonates or other prescription medications for osteoporosis. * Anyone taking chemotherapy medication. * Anyone diagnosed with hemochromatosis or elevated iron levels. * Anyone who drinks heavily (i.e. eight or more alcoholic drinks per week for women or 15 or more alcoholic drinks per week for men). * Anyone unwilling to follow the study protocol. * Anyone with a history of substance abuse. * Anyone who is currently a smoker or has been a smoker in the past three months. * Anyone who has stopped using hormonal birth control less than six months prior to starting the study. * Anyone previously diagnosed with premenstrual dysphoric disorder (PMDD), endometriosis, or any cancer of the reproductive system. * Anyone who is peri- or post-menopausal.

Locations (1)

Citruslabs

Las Vegas, Nevada, United States